# Pila Pharma Starts Dosing in 12-Week Obesity Trial

- URL: https://stocks.freetheai.org/news/pila-pharma-starts-dosing-in-12-week-obesity-trial-8b7928
- Published: 2026-10-14T12:06:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [OMXSTO:PILA](https://stocks.freetheai.org/symbols/OMXSTO-PILA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Pila Pharma AB (OMXSTO:PILA) has begun dosing participants in a 12-week clinical study evaluating its oral obesity drug candidate, XEN-D0501. The trial officially started after the first two participants received their doses within a smaller pilot cohort, which will precede a broader study expansion.

The trial is testing dosage levels up to four times higher than those previously evaluated in human studies. XEN-D0501 is an oral TRPV1 antagonist designed for obesity treatment. By utilizing a staggered pilot group, the trial design aims to manage safety risks associated with evaluating elevated dosage levels in humans.

Key upcoming milestones include safety assessments at these higher doses and monitoring potential weight-loss efficacy over the 12-week treatment period. Shares of Pila Pharma AB traded down 6.90% at 1.62 SEK on the day of the update.

## Key points

- Pila Pharma dosed the first two participants in a 12-week obesity trial for XEN-D0501.
- The study evaluates dosage levels up to four times higher than previously tested in humans.
- Dosing begins in a pilot cohort before expanding to a larger participant group.
- XEN-D0501 is an oral TRPV1 antagonist being evaluated for weight loss.
- Shares of Pila Pharma AB fell 6.90% to 1.62 SEK following the news.

## Questions and answers

### What clinical trial did Pila Pharma start?

Pila Pharma started a 12-week obesity trial evaluating its oral TRPV1 antagonist, XEN-D0501, beginning with a pilot cohort before expanding.

### How high are the doses being tested in Pila Pharma's trial?

The trial is testing doses of XEN-D0501 up to four times higher than those previously evaluated in humans.

### What is XEN-D0501?

XEN-D0501 is an oral TRPV1 antagonist being developed by Pila Pharma as a potential treatment for obesity.